(Q36981688)

17 August 2017

1 reference

title

Anti-IgE in allergic asthma and rhinitis: an update (English)

1 reference

17 August 2017

1 reference

Jaymin B Morjaria

1

1 reference

17 August 2017

Gnanasekaran Gnanakumaran

series ordinal

2

1 reference

17 August 2017

Kesavan Suresh Babu

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1739-1747

1 reference

The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Structure and functions of CD23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Omalizumab is effective in the long-term control of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Interpreting treatment effects in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Allergic rhinitis and its impact on asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Epidemiologic evidence for asthma and rhinitis comorbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Intranasal steroids and the risk of emergency department visits for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Links between rhinitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

A comprehensive study of the direct and indirect costs of adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1739

10.1517/14712598.7.11.1739

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference